Demonstrating Value: Association of Cost and Quality Outcomes With Implementation of a Value-Driven Oncology-Hospitalist Inpatient Collaboration for Patients With Lung Cancer

BMJ Open Quality - United Kingdom
doi 10.1136/bmjoq-2018-000381
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

High-Value Cancer Care and the Problem With Surrogate Endpoints in the Quality/Cost Equation

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2019English

The Prognostic Value of Neutrophil to Lymphocyte and Platelet to Lymphocyte Ratios for Patients With Lung Cancer

Oncology Letters
Cancer ResearchOncology
2017English

The Value of Commission on Cancer Accreditation: Improving Survival Outcomes by Enhancing Compliance With Quality Measures

Annals of Surgical Oncology
OncologySurgery
2019English

Prognostic Value of Plasma Fibrinogen in Lung Cancer Patients: A Meta-Analysis

Journal of Cancer
Oncology
2018English

Improving Value for Patients With Eczema

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Prognostic Value of Pleural Lavage Cytology in Patients With Lung Cancer Resection: An Updated Meta-Analysis

PLoS ONE
Multidisciplinary
2016English

Perspectives of Patients With Cancer on the Quality-Adjusted Life Year as a Measure of Value in Healthcare

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2019English

P2.15-06 Examination of Optimal Timing of Post-Surgical Surveillance for Early Stage Lung Cancer Patients and Association With Outcomes

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Value of P16INK4a and RASSF1A Promoter Hypermethylation in Prognosis of Patients With Resectable Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2004English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy